Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam.
Nguyen Bao NgocDinh-Hoa VuNguyen Thi ThuyDuong Van QuangCao Thi Thu HuyenNguyen Mai HoaNguyen Hoang AnhPhan Thuong DatNguyen Binh HoaEdine TiemersmaNguyen Viet NhungPublished in: PloS one (2021)
While a majority of patients on the longer injectable-based regimens experienced non-serious AEs during MDR-TB treatment, one in six patients experienced at least an SAE. Active TB drug-safety monitoring is useful to understand the safety of MDR-TB treatment and explore the risk factors for toxicity. All-oral, shorter MDR-TB regimens might be able to reduce the inconvenience, discomfort, and toxicity of such regimens and increase adherence and likelihood of successful completion.
Keyphrases
- multidrug resistant
- end stage renal disease
- ejection fraction
- mycobacterium tuberculosis
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- drug resistant
- emergency department
- type diabetes
- oxidative stress
- metabolic syndrome
- patient reported outcomes
- adipose tissue
- cystic fibrosis
- skeletal muscle
- insulin resistance
- hepatitis c virus
- combination therapy
- hyaluronic acid
- electronic health record